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Purpose/Objective: We retrospectively analyzed our five 
years experience with patient-specific VMAT QA using the 
PTW seven29/Octavius system and reported our institutional 
guidelines and action limits for VMAT delivery.  
Materials and Methods: Since June 2009, 1001 patients were 
treated with Elekta VMAT technique at our institution. 
Treatment plans were re-grouped according to treatment 
technique and disease sites: (1) 437 patients with high-
modulated complex treatments for head-neck, rectal, 
endometrial, brain tumours and other sites, all optimized 
with Masterplan Oncentra TPS with Simultaneous Integrated 
Boost strategy in dual-arc modality; (2) 248 patients with 
prostate tumours and (3) 316 patients with bone, liver, lung, 
abdominal and pelvic metastasis treated with high-dose 
extracranial stereotactic radiotherapy (SBRT). Group 2/3 
plans were optimized with anatomy-based Ergo++ TPS and 
treated with one arc. The absolute doses were measured 
utilizing the PTW Seven29 ion-chamber array and the 
Octavius phantom. VMAT plans were recalculated on 
phantoms representing the Octavius geometry and density; 
for each arc the doses were measured both on coronal and 
sagittal planes, for a total of 2876 measurements (in groups 1 
and 2/3, each plan underwent four and two measurements, 
respectively). Agreement of measured and predicted doses 
were evaluated using 3%(global)/3mm γ-analysis. Three 
scalar metrics were evaluated for each measurement: (a) 
percentage of points with gamma value less than one (Pg<1), 
(b) mean gamma (γmean), and (c) maximum gamma (γmax). 
Gamma results were evaluated according to treatment 
technique and disease sites and reported for each arc 
individually and on a per patient-basis. 
Results: Table 1 shows the overall γ-analysis results for all 
patients with associated confidence limits. γ pass-rate values 
significantly depend on plan complexity. For the patients in 
group (1), average Pg<1, γmean and γmax were 94.8% ± 3.8%, 0.39 
± 0.08 and 1.83 ± 0.55, respectively. These values reached 
99.1% ± 1.9%, 0.38 ± 0.08 and 0.99 ± 0.25 values in group (2) 
and 98.3% ± 2.7%, 0.32 ± 0.09 and 1.13 ± 0.45 values in group 
(3). On a per-patient basis, our local confidence limits for Pg<1 
were determined to be 10.0%, 4.0%, and 6.6%, for patients in 
group 1, 2 and 3, respectively. 
 
 
 
Conclusions: This comprehensive study shows that PTW 
seven29/Octavius system allows a reliable and accurate 
dosimetric procedure for VMAT QA, benefiting from all the 
advantages of ionization chamber absolute dosimetry. 
Despite the increased complexity in VMAT treatments, our 
local confidence limits were comparable to those of AAPM TG 
119. 
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Purpose/Objective: VMAT delivers radiation via dynamic 
multileaf collimator (MLC) motion, and allows for variable 
dose rates, gantry speed modulation, and collimator rotation. 
It is, therefore, patient-specific quality assurance (QA) for 
VMAT plans is important in confirming dose distribution. The 
COMPASS® system allows for 3D dosimetric quality assurance 
using MatriXX-specific software and the MatriXX mounted to 
the gantry with a gantry angle sensor. In this study, the 
retrospective investigation of the QA results using COMPASS 
for head and neck (H&N) VMAT cases. 
Materials and Methods: VMAT patient plans were delivered 
to the MatriXX and used to verify the 3D dose distribution 
calculated by COMPASS. QA results of 65 head and neck 
patients which were treated in our clinic with 
TrueBeam/TrubeamSTX machine consist of the 
nasopharyngeal, larynx and oral cavity tumors were analyzed. 
Compass system with MatriXX can provide an accurate three-
dimensional quantitative analysis of dose delivery. Dose 
distribution and 3D anatomical site dose differences using 
DVH were evaluated by comparing the measurements and the 
treatment planning system (TPS) calculations by using AAA 
algorithm at the Eclipse TPS. Furthermore, the investigation 
of the TPS and COMPASS dose calculation based on the 
Collapse Cone Algorithm was assessed. The COMPASS and the 
measurement dose distributions agreement was tried o obtain 
with that of a treatment planning system by gamma analysis 
(criteria; 3 mm/3%)a and the volumetric results of the 
critical organs such as spinalcord was evaluated by average 
dose value with 3% criteria. 
Results: Compass system was very sensitive to the MLC and 
dose error caused by machine. This system allows to asses 3D 
anatomical based dose difference between measurement and 
planning dose. We found that except 5 cases inside the data 
sets the relative dose differences agreement within the dose 
volume criteria for spinalcord. All parotid glands dose 
differences were inside the dose acceptance criteria except a 
case which shows 4,03%. For all cases, CTV and GTV dose 
agreement was archived inside the gamma criteria. 
Conclusions: The COMPASS system can be expected to be 
used for traditional QA methods in clinical routine for QA of 
VMAT plans. The Compass allows anatomical dose distribution 
evaluation to decide acceptable treatment plan. 
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Purpose/Objective: We routinely use entrance point In vivo 
dosimetry (IVD) for electron boost in breast treatments. From 
the histogram of differences between measured and 
predicted doses in 158 patients, we found a shift of 1.6% and 
observed that 10% of the results were out of tolerance (>7%). 
We studied whether breast shape and lung could explain this 
histogram shift and the outliers.  
Materials and Methods: We used 9 and 16 MeV electron 
beams delivered by a Clinac 2100C/D (Varian). We calibrated 
a set of Electron QED diodes (Sun Nuclear) against the dose 
measured at the depth of dose maximum zcal (entrance 
dose) for both energies for a 10x10 cm2 applicator and 
SSD=100cm. We applied correction factors (CF) for the 
applicator when needed. Entrance IVD consisted of 
comparing diode dose measurements with the dose 
calculated by the TPS at central axis and zcal. Dose 
calculations were performed with Eclipse eMC algorithm, 
v.8.9 (Varian). To evaluate lung tissue impact on IVD, we 
performed entrance IVD for a set of phantoms combining 
water equivalent slabs (CIRS) simulating different thicknesses 
of chest wall, followed by lung equivalent slabs (CIRS). The 
distance from zcal to tissue lung interface (d) characterized 
each phantom. All results were referenced to those of a 
homogeneous plastic water phantom (d= 40cm). A 10x10cm2 
applicator was used. To evaluate the impact of breast shape, 
we used a QUASARTM phantom (Modus Medical Devices). We 
measured entrance doses on the phantom’s flat surface 
keeping angle gantry at 00 and on its curved surface keeping 
angle gantry at 2700. This was performed for 6x6 and 10x10 
cm2 applicators. Using the same geometry, we calculated the 
entrance dose under the flat and curved surfaces (accuracy 
1%).  
Results: Diode dose measurements on the top of the 
phantoms with lung slabs did not differ more than 0.5% from 
measurements on the top of the plastic water phantom. 
However, calculated entrance doses for all phantoms varied 
up to 25%. Figure I shows how entrance calculated doses 
decreased with d. These results indicate that differences 
between measured and calculated entrance doses will be 
larger than 10% when zcal falls within lung tissue, without any 
other cause. When placed on the top of the flat and curved 
surfaces, diode dose measurements did not differ more than 
0.4%. Entrance dose calculation under the curved surface 
was, on average, 2% lower than calculations under the flat 
surface.Table 1 shows there was a slight dependence on 
energy and the applicator. These findings show that without 
any other cause the diode will overestimate entrance dose in 
about 2% due to the curvature effect caused by breast shape. 
 
 
 
 
Conclusions: Lung study results explain most histogram 
outliers. A CFlung, function of d, could be applied to diode 
readings before they are compared with predicted doses. The 
2% overestimation of entrance dose when measuring on a 
curved surface is related to histogram shift, but it is difficult 
to determine patient’s CFshape and further studies must be 
done. 
   
EP-1397   
Evaluation of superficial dose for Postmastectomy using 
several treatment techniques 
Y.M. Song1, J.M. Choi1, J.M. Kim1, D.Y. Kwon1, J.S. Kim1, H.S. 
Cho1, K.W. Song1 
1Samsung Medical Center, Radiation Onclogy, Seoul, Korea 
Republic of  
 
Purpose/Objective: The purpose of this study was to 
evaluate the surface and superficial dose for patients 
requiring postmastectomy radiation therapy(PMRT) with 
different treatment techniques 
Materials and Methods: Computed tomography images were 
acquired for the phantom(I`mRT, IBA) consisting of tissue 
equivalent material. Hypothetical chestwall and lung were 
outlined and modified. Five treatment techniques(Wedged 
Tangential; WT, 4-field IMRT, 7-field IMRT, TOMO DIRECT, 
TOMO HELICAL) were evaluated using only 6MV photon beam. 
GafChromic EBT3 film was used for dose measurements at 
the surface and superficial dose. The surface dose was 
measured by placing film onto the phantom surface and 
profiles around the phantom were obtained for each 
treatment technique. For superficial dose measurements, 
film were used inside the phantom and analyzed superficial 
region for depth from 1-6mm. 
Results: TOMO DIRECT showed the highest surface dose by 
47~70% of prescribed dose, while 7-field IMRT showed the 
lowest by 35~46% of prescribed dose. For the WT, 4-field 
IMRT and 7-field IMRT, superficial dose were measured over 
60%, 70%, and 80% for 1mm, 2mm, and 5mm depth, 
respectively. In case of TOMO DIRECT and TOMO HELICAL, 
over 75%, 80%, and 90% of prescribed dose was measured, 
respectively. Surface and superficial dose range were uniform 
in overall chestwall for the 7-field IMRT and TOMO HELICAL. 
In contrast, Because of the dose enhancement effect with 
oblique incidence, The dose was gradually increased toward 
the obliquely tangential angle for the WT and TOMO DIRECT.  
Conclusions: For PMRT, Superficial doses are affected by the 
treatment technique.TOMO DIRECT and TOMO HELICAL 
